. [eighty two] to evaluate the efficacy, security and tolerability of Cannabidiol being an adjunct therapy as well as anti-epileptic medicines to the clients suffering from tuberous sclerosis advanced whose commonest neurological symptom is epilepsy. During this clinical trial research, right after therapy with Cannabidiol, responder price from the